TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 6 month progression-free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Complete Response or Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of gastroduodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of Pain During Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organoleptic Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl Meyer Score for sensorymotor recovery of the upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Clearance and removal rate of phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clearance and removal rate of beta2 microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance and removal rate of leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Total Nasal Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Adverse Drug Reactions (ADRs) and Unexpected ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Glycosylated Haemoglobin (HbA1c) at Weeks 13 and 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants with Glycosylated Hemoglobin < 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Subjects With a ≥50% Reduction in Pads Per Day Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Life Scores as Compared to Baseline for I-QOL, ICIQ-SF, and Summary of Values for the PGI-I
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Adverse Events Reported Between Arms
Endpoint domain: Adverse events/effects
Primary endpoint: Positive predictive value of the Hevylite test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early detection of OSCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Improvement in the Sartorius Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interferon alpha, beta, lambda levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: treatment failure at 3 years after cryoablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day survival rate with favorable neurological status
Endpoint domain: Mortality/survival
Primary endpoint: IQ as measured by the WISC III Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to adequate symptom control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects for each adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Effect to Body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect to Pulse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effect to Respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Effect to Systolic blood pressure in sitting position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effect to Diastolic blood pressure in sitting position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Survival Rate at 5 Years
Endpoint domain: Mortality/survival
Primary endpoint: 6 Minutes walking distance (change in meters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Annual Change in estimated glomerular filtration rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of End-stage Renal Disease (ESRD)
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Quality of Life (adults patients)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Quality of Life (pediatric patients)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Molecular biomarkers for lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adherence to direct oral anticoagulants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incremental Change in Fatigue Score From Baseline to Week 12
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: AUC of grand averaged mean differences between ERPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma degarelix PK profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Trough plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite of major adverse cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Degree of nausea and vomiting after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of pain after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-12/24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence status based on pathology results
Endpoint domain: Mortality/survival
Primary endpoint: Change in Percent Predicted Absolute Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary vascular permeability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of solicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of time with pH below 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of awareness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Level of pain and discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of NRS-A Pain Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of frames with in stent-lipid laden neointima, neovascularization, calcification and thin-cap fibro-atheroma (TFCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: length of consecutive frames with uncovered struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients Receiving RAASi Treatments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Urine metabolite profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lung dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sleep questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: First recurrence of Plasmodium vivax malaria
Endpoint domain: Mortality/survival
Primary endpoint: Interfraction prostate bed motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrafraction prostate bed motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Intervention-Recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of Intervention-Withdrawals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability of Lifestyle PA Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: offspring weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autoimmune response to AIPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Caffeine urinary molar ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dextromethorphan urinary molar ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment-Emergent Adverse Events (TEAs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline of Glabellar Lines improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Multiscale Dissociation Inventory (MDI) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modified PTSD Symptom Scale (MPSS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Kentucky Mindfulness Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Multidimensional Assessment of Interoceptive Awareness Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Uptake - referral rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Uptake - completion rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Normalisation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Efficiency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mesenchymal gene expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of cryotherapy in treating solar lentigo spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of patients obtaining a negative Minimal Residual Disease (MRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of fecal ETEC numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of total daily fecal output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cmax (Maximum concentration of drug in serum)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt (Area under the plasma concentration-time curve from time zero to time t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hand Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Narcotic Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal Tip Projection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Lip Projection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: circulating endocannabinoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of biomarkers CRP, PCT, WBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Assessment of patients' immune status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Determination of cytokines level in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Core muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensorimotor control of core musculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline pain intensity at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline physical function at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Mucociliary Clearance Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: composite event of death, myocardial infarction, TVR, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change in degree of disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of Patients With Complete and Partial Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Patients With Adverse Events as Assessed by CTCAE v4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of the quality of imaging sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter observer registration variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary excretion of melamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary excretion of five DEHP metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Regional brain/spine volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diffusion scalars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: biopsy-proven acute rejection
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of participants retained in the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Satisfaction, measured by the satisfaction survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Cardiac Output (CO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Mean Pulmonary Artery Pressure (mPAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of waistline girth measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Rating Scores for foot and ankle pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peritoneal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucose loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: healing rate of diabetic foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: recurrence rate of diabetic foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Major Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change in state of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in factors impacting well-being of caregivers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bond between parents and children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rate of stroke recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Long term effect of crystallized phenol treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasma concentration of atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response rate (complete and partial responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients developing pancreatic fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients developing hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients developing wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: Filling rate of the application
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pathological changes in the heart and lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infection of Covid-19
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of 25-hydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of parathyroid hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma concentrations of alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe anoxic brain injury
Endpoint domain: Mortality/survival
Primary endpoint: thermal and pressure pain sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reinfection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Number of deaths (all cause)
Endpoint domain: Mortality/survival
Primary endpoint: amount of rescue medicine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sparing of organs at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of D390 and CKD-375
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of D390 and CKD-375
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: K1 parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ki parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of Perceived Maternal Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urticaria Activity Score (7 day cumulative score - UAS7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in clinical chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of secondhand smoke exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine NNAL (4-(Methylnitrosamine)-1-(3-pyridyl)-1-butanol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normal glycemic control without insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of late-onset sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: 6 Minutes Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of social medical progression of coronary heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum non-transferrin bound iron (NTBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Women's ratings of emotional well being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anti-inflammatory Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ongoing pregnancy at 20 weeks
Endpoint domain: Mortality/survival
Primary endpoint: salivary chemerin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary fetuin-A level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary IL-34 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary IL-13 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: presence of perforation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence of perforation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in audiometric measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of HepaGam B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of focal ablation of prostate lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Naming and Word Finding Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Basal Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sensitivity of plasma circulating tumor DNA detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of plasma circulating tumor DNA detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Achieved Maternal 25(OH)D Level of ≥ 30 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute kidney injury as reflected by a rise in creatinine or urinary biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of Viral Rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: VAS (visual analog scale) pain intensity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes